Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Sep 25, 2026 · Filed Sep 28, 2026
The CEO of Damora Therapeutics paid $253K out of pocket for Damora Therapeutics shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$252,875
Shares × reported transaction price
$100K–$500K
+2.5%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
None found in footnotes
Only flagged when a footnote says so; never inferred
The first open-market purchase by any DMRA insider since Mar 2022. Jennifer Jarrett's first open-market purchase of DMRA in filings since 2020
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −5.4% | +1.9% | −7.3% |
| 30 days | +6.5% | +0.7% | +5.8% |
Past results only. Not a forecast.
